The Testing Evidence for Using Ivermectin for Treating Ovarian Cancer
Executive Summary
- Ivermectin is proven to treat a variety of different cancers.
- Ovarian cancer is one of them.
Introduction
In a previous article titled How Ivermectin Is Useful for Treating Cancer we covered the evidence for the benefits of Ivermectin for cancer. But the question of which cancers Ivermectin has been proven to be effective is a constant source of questions.
This article provides an overview coverage of these specific cancers.
There are a lot of quotes in this article, but I have a short one for each cancer type. The article uses the term “IVM” to mean Ivermectin.
Cancer Type #6:Ovarian Cancer
Ovarian cancer is a malignant cancer that lacks early clinical symptoms and has a poor therapeutic response. The 5-year survival rate after diagnosis is approximately 47% [27,57]. In a study by Hashimoto, it found that IVM inhibited the proliferation of various ovarian cancer cell lines, and the mechanism was related to the inhibition of PAK1 kinase [58]. In research to screen potential targets for the treatment of ovarian cancer through the use of an shRNA library and a CRISPR/Cas9 library, the oncogene KPNB1 was detected. IVM could block the cell cycle and induce cell apoptosis through a KPNB1-dependent mechanism in ovarian cancer [59]. Interestingly, IVM and paclitaxel have a synergistic effect on ovarian cancer, and combined treatment in in vivo experiments almost completely inhibited tumor growth. Furthermore, according to a report by Zhang, IVM can enhance the efficacy of cisplatin to improve the treatment of epithelial ovarian cancer, and the mechanism is related to the inhibition of the Akt/mTOR pathway [60].
IVM has been proven to significantly inhibit the proliferation and migration of HeLa cells and promote apoptosis. In a study by Hashimoto, it found that IVM inhibited the proliferation of various ovarian cancer cell lines, and the mechanism was related to the inhibition of PAK1 kinase. – NIH
The Importance of The NIH Stopping Any Funding For Ivermectin Studies
Notice that none of the studies on Ivermectin were performed in the US. The US has by far the largest national medical research budget in the world, and so if the US is not performing studies, this is not only a negative but tells us something peculiar about what the NIH is deciding not to fund in the area of cancer research.
Zero is the number of studies funded by the NIH on Ivermectin. The NIH will not fund studies into generic drugs, as the NIH is controlled by pharmaceutical companies and they have deep financial ties to them. Funding research into generic drugs could end up showing those drugs as effective, which is a threat to pharmaceutical profits, which the NIH is dedicated to maximizing.
Increases in Ovarian Cancer Due to the Covid Vaccines
Rates of ovarian cancer have greatly increased. This is explained in the following quotation.
This is significant because official data from the U.K. recently showed that the cases of ovarian cancer in 2021 were at a record high. Also last year, the Medicines and Healthcare products Regulatory Agency (MHRA), the U.K.’s drug regulator, received more than 40,000 reports linked to reproductive and menstrual disorders that were suspected as adverse reactions to the vaccines. – Cancer News
More on evidence for the concentration of spike proteins in the ovaries of mice is found in the following quote.
Wistar Han rats (21 male and 21 female) each received a single intramuscular dose of [3H]-08-A01-C01 at a target mRNA total dose of 50 µg/animal (1.29 mg/animal total lipid dose). The content and concentration of total radioactivity in blood, plasma and tissues were determined at pre-defined time points following administration.
Whole blood and tissue samples were collected at 0.25 1, 2, 4, 8, 24 and 48 hours post-dose (three animals/sex/timepoint) and plasma was subsequently separated from blood by centrifugation. The concentration of total radioactivity was measured by liquid scintillation counting (LSC). – A Tissue Distribution Study of a [3 H]-Labelled Lipid Nanoparticle-mRNA Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rats
Regarding dosage and sourcing of Ivermectin, see the article On the Topic of Ivermectin Dosage and Sourcing.
Regarding dosage and sourcing of Ivermectin, see the article On the Topic of Ivermectin Dosage and Sourcing.
Why Are Anti Parasitic Drugs Effective Against Cancer?
If you are interested in understanding why this class of drugs works against cancer, see the article The Mechanism of How Anti Parasitic Drugs Work to Mitigate Cancer.